Headlines

AbbVie (ABBV) lowers 2025 adj. EPS guidance to USD 9.90-9.94 including milestones expense; Q4 25 view adj. EPS 2.61-2.65

Newsquawk Staff ·

AbbVie (ABBV) lowers 2025 adj. EPS guidance to USD 9.90-9.94 including milestones expense; Q4 25 view adj. EPS 2.61-2.65.

What it means

AbbVie's revision of its 2025 adjusted EPS guidance down to USD 9.90-9.94 reflects increased milestone expenses, which could signal underlying pressures on profitability. This may also influence investor sentiment, as adjusted EPS for Q4 2025 is projected between 2.61-2.65, suggesting cautious outlook for growth amidst ongoing financial adjustments. Watch for potential sector implications, particularly in biotechnology, and how this shapes investor expectations in upcoming sessions.

Related headlines